No Effect of an Automated Bolus Calculator in Pediatric Patients with Type 1 Diabetes on Multiple Daily Injections: The Expert Kids Study

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review


  • Jens Otto Broby Madsen, Amtssygehuset i Herlev
  • ,
  • Kristina Casteels, University of Leuven, Leuven, Department of Paediatrics, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • ,
  • Steffen Fieuws, University of Leuven
  • ,
  • Kurt Kristensen
  • Koen Vanbrabant, Leuven University, Belgium
  • ,
  • Marta Ramon-Krauel, Hospital Sant Joan de Deu
  • ,
  • Jesper Johannesen, Amtssygehuset i Herlev, Københavns Universitet

Background: This multicenter crossover study investigated the potential beneficial effect of an automated bolus calculator (ABC) in children and adolescents with type 1 diabetes (T1D) treated with multiple daily injections (MDI). Methods: Participants were randomized to either begin or end with a 5 months intervention versus their regular treatment regimen (control), separated by a 2 months washout period. During the intervention participants were carefully instructed to use the ABC (Accu-Check Aviva Expert) versus manual insulin calculations during the control period. Participants between 8 and 18 years of age with T1D were recruited from clinics in Denmark, Belgium, and Spain. Inclusion criteria included T1D for >1 year, a minimum of 3 months MDI treatment before inclusion, and HbA1c of 7.5%-11% (57-97 mmol/mol). Improvement in HbA1c was the main outcome, and improved quality of life (QoL) and glucose variability (time spent in target glucose) were secondary outcomes. Results: A total of 65 patients with a mean age of 13.25 years and a mean HbA1c of 8.25% (66.7 mmol/mol) were included. Midway evaluation after 2 months of intervention showed no significant difference from the standard care (0.297, 95% confidence interval [CI]: -0.645 to 0.054; P = 0.10). The difference remained insignificant after the 5 months of intervention (-0.143 [95% CI: -0.558 to 0.272; P = 0.51]). Using the ABC did not change the time spent in target glucose range, nor did it change the QoL. Conclusions: Our study did not demonstrate beneficial additive effects of an ABC in children and adolescents with T1D treated with MDI neither in HbA1c, nor in any other endpoint investigated.

TidsskriftDiabetes Technology and Therapeutics
Sider (fra-til)322-328
Antal sider7
StatusUdgivet - jun. 2019

Se relationer på Aarhus Universitet Citationsformater

ID: 156599672